Tempero Bio Secures $70 Million Series B Financing to Advance TMP-301 into Phase 2 Trials for Substance Use Disorders
Summary
We urgently need more effective treatments to help patients and families with these diseases," said Ricardo Dolmetsch, Ph.D., President and Chief Scientific Officer of Tempero Bio. None A Phase 2 study in cocaine use disorder is planned following the completion of the DDI study.The addiction crisis remains a significant public health challenge. Before joining Tempero Bio, Dr. Wagner served as Chief Medical Officer at Koneksa Health and Cygnal Therapeutics, held senior leadership positions at Takeda and Merck, and was a venture partner at Foresite Capital. Additionally, he currently serves as Editor-in-Chief of Clinical and Translational Science and holds an executive committee position with the Foundation for the National Institutes of Health Biomarkers Consortium.Tempero Bio is a clinical-stage biopharmaceutical company committed to developing innovative treatments for substance use disorderschronic, relapsing brain diseases with limited pharmacologic solutions. For more information, visit .Aditum Bio accelerates the development of high-impact therapies by in-licensing promising drug candidates, forming dedicated companies, and advancing them through clinical trials.